Press Releases 2023 2022 2021 2020 2019 all September 6, 2022 Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference September 6, 2022 Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 September 6, 2022 Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy August 29, 2022 Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development August 10, 2022 Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research August 4, 2022 Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights July 12, 2022 Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 July 5, 2022 Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy June 3, 2022 Dyne Therapeutics to Present at Jefferies Global Healthcare Conference May 16, 2022 Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown May 2, 2022 Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights March 10, 2022 Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights March 3, 2022 Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors January 18, 2022 Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy January 5, 2022 Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference December 2, 2021 Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy November 4, 2021 Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights October 13, 2021 Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day October 1, 2021 Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin Expression September 28, 2021 Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021 Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Next page › Last page » Displaying 21 - 40 of 77
